India, Nov. 5 -- Dyne Therapeutics, Inc. (DYN), a clinical-stage biotechnology company focused on developing treatments for genetically driven neuromuscular diseases, reported third-quarter 2026 financial results and provided updates on its clinical and preclinical programs.
The company is advancing its investigational therapies for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), while progressing additional preclinical programs targeting multiple DMD mutations.
Third Quarter 2026 Financial Results
For the three months ended September 30, 2026, net loss increased to $193.6 million, or $1.06 per share, compared with a net loss of $108.0 million, or $0.76 per share, in the prior-year quarter.
Research and developmen...